CPT® Code 87327

1. Indications

The CPT® Code 87327 is indicated for the detection of Cryptococcus neoformans antigen in patients who may be at risk for infections caused by this organism. The following conditions and symptoms may warrant the use of this test:

• Immunocompromised Status Patients with weakened immune systems, such as those with HIV/AIDS, cancer, or those undergoing immunosuppressive therapy, are at higher risk for infections caused by Cryptococcus neoformans.
• Signs of Meningitis Individuals presenting with symptoms consistent with meningitis, such as severe headache, fever, neck stiffness, and altered mental status, may require this test to confirm or rule out cryptococcal infection.
• Pneumonia Symptoms Patients exhibiting respiratory symptoms, including cough, chest pain, and difficulty breathing, may be tested for Cryptococcus neoformans if there is a suspicion of pulmonary involvement.
• Monitoring Treatment Response The test may also be used to monitor the effectiveness of treatment in patients diagnosed with cryptococcal infections, assessing the presence or absence of the antigen over time.

2. Procedure

The procedure for conducting the test associated with CPT® Code 87327 involves several key steps to ensure accurate detection of the Cryptococcus neoformans antigen:

• Sample Collection A biological sample, typically cerebrospinal fluid (CSF), is collected from the patient. This sample may be obtained through a lumbar puncture or other appropriate methods, depending on the clinical scenario.
• Sample Preparation The collected sample is either placed in a fixative to preserve its integrity or sent fresh to the laboratory for immediate processing. Proper handling of the sample is crucial to avoid degradation of the antigen.
• Immunoassay Technique Selection The laboratory technician selects the appropriate immunoassay technique for the test, which may include EIA, ELISA, FIA, or IMCA, based on the laboratory's capabilities and protocols.
• Antigen Detection The selected immunoassay technique is performed, where the sample is mixed with specific antibodies that bind to the Cryptococcus neoformans antigen. In EIA and ELISA, a secondary enzyme-labeled antibody is added to facilitate detection, while FIA uses a fluorescent compound, and IMCA employs a chemiluminescent substance.
• Result Interpretation The results are assessed through colorimetric readings, fluorescence detection, or light emission, depending on the technique used. The presence of a color change, fluorescence, or light emission indicates the presence of the antigen, which is then reported as qualitative or semi-quantitative results.

3. Post-Procedure

After the procedure, the laboratory will analyze the results and report them to the requesting physician. It is essential for healthcare providers to interpret the results in the context of the patient's clinical presentation and history. If the test is positive, further clinical evaluation and management may be necessary, particularly for immunocompromised patients. Follow-up testing may be required to monitor the patient's response to treatment or to confirm the resolution of the infection. Additionally, proper documentation of the test results and any subsequent actions taken is crucial for maintaining compliance and ensuring continuity of care.